| 000 | 03216nam a22004455i 4500 | ||
|---|---|---|---|
| 006 | a||||fo|||| 00| 0 | ||
| 007 | cr nn nnnaamaa | ||
| 999 |
_c329552 _d329552 _x1 |
||
| 001 | 329552 | ||
| 003 | ES-MaUEC | ||
| 005 | 20230102114421.0 | ||
| 008 | 201128s2020 gw | s |||| 0|eng d | ||
| 020 | _a9783030573782 | ||
| 024 | 7 |
_a10.1007/978-3-030-57378-2 _2doi |
|
| 040 |
_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC |
||
| 050 | 4 |
_aRC931.O73 _b2020 EB |
|
| 245 | 0 | 0 |
_aBone Regulators and Osteoporosis Therapy _cedited by Paula H. Stern. |
| 250 | _aPrimera edición 2020. | ||
| 264 | 1 |
_aCham _bSpringer International Publishing : _bImprint: Springer _c2020. |
|
| 300 |
_a1 recurso en línea (X, 518 páginas) _b1 ilustración |
||
| 336 |
_2rdacontent _aTexto _btxt |
||
| 337 |
_2rdamedia _aelectrónico _bc |
||
| 338 |
_2rdacarrier _arecurso electrónico _bcr |
||
| 347 |
_atext file _bPDF |
||
| 490 | 0 |
_aHandbook of Experimental Pharmacology _x0171-2004 _v262 |
|
| 490 | 0 | _aBiomedical and Life Sciences (SpringerNature-11642) | |
| 490 | 0 | _aBiomedical and Life Sciences (R0) (SpringerNature-43708) | |
| 505 | 0 | _aThe cells of bone their interactions -- Parathyroid hormone and bone -- Vitamin D and bone -- Gonadal hormones and bone -- Thyroid hormones, glucocorticoids, insulin, and bone -- Growth factors and bone -- Prostaglandins and bone -- Cytokines and bone: osteoimmunology -- Chemokines and bone -- Calcium and bone -- FGF-23 and bone and mineral metabolism -- Nervous system mediators and bone -- Genetics of bone disorders -- Osteoporosis pathogenesis -- Structural and metabolic assessment of bone status -- Osteoporosis Therapeutics 2019 -- New targets and emergent therapies for osteoporosis -- Drugs causing bone loss -- Natural Products as potential bone therapies. | |
| 520 | 3 | _aThis volume is designed to provide an understanding of current and potential therapies for osteoporosis. The opening chapter introduces the cells of bone and their interactions. Several following chapters describe factors affecting bone including systemic hormones with significant effects on bone, and local mediators including growth factors, prostaglandins, cytokines and chemokines. Topics that have commanded particular attention recently are calcium, FGF-23, nervous system bone interactions. Drugs that cause bone loss provide important information on mechanism as well as therapeutic considerations. An overview of the genetics of bone disorders and a discussion of the pathophysiology of osteoporosis establish the clinical context. The final chapters discuss current and potential osteoporosis treatments. . | |
| 988 | _aSpringer_BiomedLife_dic2020 | ||
| 650 | 7 |
_2embne _9141478 _aOsteoporosis |
|
| 700 | 1 |
_aStern, Paula H _eeditor literario _4http://id.loc.gov/vocabulary/relators/edt |
|
| 710 | 2 | _aSpringerLink | |
| 773 | 0 | _tSpringer Nature eBook | |
| 776 | 0 | 8 |
_iPrinted edition: _z9783030573775 |
| 776 | 0 | 8 |
_iPrinted edition: _z9783030573799 |
| 776 | 0 | 8 |
_iPrinted edition: _z9783030573805 |
| 856 | 4 | 0 |
_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-57378-2 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 942 |
_2lcc _cLE |
||
| 998 |
_b01/2021 _dz _eIG _zSI |
||